Viking Therapeutics Inc. (VKTX)
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $40.25, indicating a +1.19% shift from the previous trading day.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX NEW YORK, December 27, 2024 (PRNEWSWIRE)Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?
The weight-loss biotech Viking Therapeutics (VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (MRK -1.48%).
Why Viking Therapeutics Tumbled by More Than 10% This Week
News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period as a result.
Viking Therapeutics: Competition Fears Are Exaggerated
Viking Therapeutics' VK2735 reported promising results in February, with significant weight loss, however, shares have returned to prices before reporting VENTURE Phase II results. The company's pipeline includes VK2809 for NASH, adding value beyond VK2735's weight-loss potential. Competition concerns are overblown; Viking's dual GLP-1/GIP agonist has competitive advantages over single-mechanism therapeutics, and concern regarding small-molecule candidates is as yet unfounded.
Here's Why VKTX Stock Plummeted 18% on Wednesday
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.
What's Going On With Viking Therapeutics Stock On Wednesday?
On Wednesday, Merck & Co Inc MRK and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
